Dementia Risk and Body Fat; Cannabis Placebo Response; Epilepsy-Depression Link

Higher fat mass — especially gynoid fat in women — was linked with decreased dementia risk, which may be explained in part by reverse causality. (Alzheimer’s & Dementia)

Even at subspecialty clinics, a broad range of disorders were misdiagnosed as autoimmune encephalitis, a retrospective study showed. (JAMA Neurology)

Cerebrospinal fluid microtubule-binding region tau measures identified corticobasal degeneration with up to 89% accuracy. (Nature Medicine)

A meta-analysis showed a significant pain reduction among people randomized to placebo in clinical trials of cannabis-based therapies. (JAMA Network Open)

Alcohol use disorder was associated with higher risks of Alzheimer’s and Parkinson’s diseases, U.S. insurance claims data showed. (Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring)

Klotho protein levels differed in various clinical stages of Alzheimer’s disease and were associated with amyloid and tau levels. (JAMA Network Open)

The investigational NMDA receptor antagonist AXS-05 met its primary endpoint in the ACCORD phase III trial of Alzheimer’s agitation, Axsome Therapeutics said.

Microglial activation protected against tau accumulation in people with underlying Alzheimer’s pathology who did not have dementia. (Nature Aging)

A phenobarbital sodium powder for injection (Sezaby) was approved for neonatal seizures, Sun Pharma announced.

Depression and epilepsy share a long-term bidirectional relationship, Danish registry data showed. (Neurology)

Upper limb nerve transfer surgery improved motor strength and increased functional independence in people with tetraplegia. (JAMA Network Open)